CLAIMS

1. A solid pharmaceutical composition comprising
    a) 0.5-60 mg semaglutide;
    b) 1-50 mg dapagliflozin;
    c) 20-800 mg, such as 50-600 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC); and
    d) 0.6-30 mg, such as 1-50 mg, lubricant;

    wherein said salt of NAC constitutes at least 90 %(w/w), such as at least 95 %(w/w), of the excipients of the composition.

2. The solid pharmaceutical composition according to claim 1, wherein said composition essentially consists of:
    a) semaglutide;
    b) dapagliflozin;
    c) a salt of NAC; and
    d) at least one lubricant.

3. The solid pharmaceutical composition according to any of the preceding claims, wherein the lubricant is magnesium stearate or glyceryl dibehenate.

4. The solid pharmaceutical composition according to any of the preceding claims, wherein the composition is for oral administration, such as in the form of a tablet.

5. The solid pharmaceutical composition according to any of the preceding claims, wherein said salt of NAC constitutes at least 60 %(w/w), such as at least 75 %(w/w) or at least 80 %(w/w), of the composition.

6. The solid pharmaceutical composition according to any of the preceding claims, wherein the composition comprises 1-10 mg, such as 2-5 mg or 2-3 mg, lubricant per 100 mg of said salt of NAC.

7. The pharmaceutical composition according to any of the preceding claims, wherein the lubricant is magnesium stearate.

8. The solid pharmaceutical composition according to any of the preceding claims, wherein dapagliflozin is selected from the group consisting of: dapagliflozin propylene glycol solvate hydrate, dapagliflozin citrate (1:1), and dapagliflozin di-L-proline (1:2).

9. The solid pharmaceutical composition according to any of the preceding claims, wherein the salt of NAC is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

10. The solid pharmaceutical composition according to any of the preceding claims, wherein the tablet has a weight of 100-800 mg.

11. A solid pharmaceutical composition, wherein a dose unit comprises
    a) 1-60 mg semaglutide,
    b) 5-25 mg dapagliflozin (such as 10 mg),
    c) 50-600 mg SNAC, and
    d) 1-50 mg lubricant, such as magnesium stearate.

12. A solid pharmaceutical composition, wherein a dose unit comprises
    a) 1-60 mg semaglutide,
    b) 5-25 mg dapagliflozin,
    c) 100-300 mg SNAC, and
    d) 1-30 mg magnesium stearate.

13. A solid pharmaceutical composition according to any of the preceding claims for use in medicine.

14. A solid pharmaceutical composition according to any of claims 1-12 for use in the treatment of diabetes and/or obesity.